Cholinergic Drugs in Pharmacotherapy of Alzheimer's Disease

Authors: Camps P.; Munoz-Torrero D.

Source: Mini Reviews in Medicinal Chemistry, Volume 2, Number 1, February 2002 , pp. 11-25(15)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

The cholinergic hypothesis of Alzheimer's disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimer's disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M1 muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.

Keywords: Cholinergic Drugs; Alzheimers disease; muscarinic agonists; acetylcholine (ACh); Potassium Channel Blockers; Aminoacridines; N-Benzylpiperidines; xanomeline; muscarine

Language: English

Document Type: Review article

DOI: 10.2174/1389557023406638

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy